Description
Retatrutide is an investigational triple‑agonist peptide that activates the GLP‑1, GIP, and glucagon receptors, influencing glucose regulation, appetite signaling, and energy expenditure. By stimulating these metabolic pathways simultaneously, it enhances insulin secretion when glucose is present, slows gastric emptying, suppresses appetite centers in the brain, and increases calorie burning through glucagon receptor activity. Clinical trials have shown substantial reductions in body weight and improvements in blood sugar control in individuals with obesity and type 2 diabetes. In simple terms, retatrutide is being studied as a powerful next‑generation weight‑loss and metabolic therapy designed to help people eat less, burn more calories, and improve blood sugar levels. It is still under clinical development and not yet FDA‑approved.
Reviews
There are no reviews yet.